First Year Analysis of Lu-177 Dotatate and 1-131 MIBG


Two new therapies gained FDA approval a year ago: Luthathera™[Lutetium-177 Dotatate] and Azedra™[I-131 Iobenguane]. Luthathera™ is the first radioactive drug approved to treat adult patients with advanced neuroendocrine tumors that affect the pancreas or gastrointestinal tract. Azedra™ is the first approved treatment for MIBG-avid malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma. Hear two leading physicians from the University of Texas MD Anderson Cancer Center share their largely positive experiences with the new therapies.

Pharmacist Learning Objectives

At the completion of this application-based activity, participants will be able to:

  1. Provide a review of the data and experience on the diagnosis of GEP-NETs type tumors.
  2. Give a review of the diagnosis and treatment of pheochromocytoma and malignant paraganglioma.
  3. Discuss the local management of both disease states.
  4. Provide an overview of the treatment experience, focusing on safety and monitoring of patients undergoing therapy.

Joint Providership

This activity is approved for Board Certified Nuclear Pharmacist (BCNP) recertification credits.

Daniel Halperin, MD
Medical Oncologist
University of Texas MD Anderson Cancer Center
Beth Chasen, MD
Associate Professor
MD Anderson Cancer Center
Learning Level: Level 2
Track: Nuclear Pharmacy
Session Time Slot(s): 
Saturday, March 21
7:00 AM - 9:00 AM
Gaylord National Resort - Chesapeake A-C
ACPE Pharmacist: 0202-0000-20-032-L01-P
CEUs Pharmacist: 0.2
Activity Type: